Search
forLearn
5 / 801 resultslearn Sodium PCA
learn panthenyl ethyl ether
learn zinc PCA
learn ORPL
Research
5 / 1000+ resultsresearch Contrast-Enhanced Ultrasound (CEUS) Evaluation of Canine Prostatic Hyperplasia before and after Osaterone Acetate Therapy: Preliminary Results
Osaterone acetate reduces prostate size and enzyme levels in dogs with benign prostatic hyperplasia.
research Transient Ca2+ entry by plasmalogen-mediated activation of receptor potential cation channel promotes AMPK activity
Plasmalogens activate a channel in cells that may stimulate hair growth.
research The semiotics of breast cancer: Signs, symptoms, and sales
The paper concludes that breast cancer treatment involves complex interactions between medical symptoms, patient experiences, and commercial influences, requiring a holistic approach.
research Study on the mechanism of cadmium chloride pollution accelerating skin tissue metabolism disorder, aging and inhibiting hair regeneration
Cadmium chloride pollution can cause skin disorders, speed up aging, and prevent hair growth.
research Measurement of Steroid Hormones in Hair: an Analysis of Hormone Dynamics in Hair Follicles
The method accurately measures steroid hormones in hair to study hormone dynamics related to hair loss.
Community Join
5 / 1000+ resultscommunity A warning to anyone considering 3rd party sourcing PP405 or its analogs
Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.
community I have Post PP405 Syndrome(PPS). Should I start a foundation?
The conversation humorously discusses the fictional "Post PP405 Syndrome" and the idea of starting a foundation or cult around it. It mentions skepticism about the effectiveness of PP405 and jokes about future therapies.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community is there any news about pp405 please
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.